Silence Therapeutics plc
SLNCF
$0.95
$0.451490.53%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 1,619.15% | 96.99% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1,619.15% | 96.99% | |||
| Cost of Revenue | -37.28% | 8.47% | |||
| Gross Profit | 1,196.40% | 17.48% | |||
| SG&A Expenses | -6.95% | 9.24% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -39.07% | 29.10% | |||
| Operating Income | 123.10% | -26.88% | |||
| Income Before Tax | 149.28% | -78.37% | |||
| Income Tax Expenses | 319.84% | -72.71% | |||
| Earnings from Continuing Operations | 129.41% | -79.05% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 129.41% | -79.05% | |||
| EBIT | 123.10% | -26.88% | |||
| EBITDA | 123.73% | -27.06% | |||
| EPS Basic | 129.31% | -77.81% | |||
| Normalized Basic EPS | 149.11% | -77.12% | |||
| EPS Diluted | 129.31% | -77.81% | |||
| Normalized Diluted EPS | 149.11% | -77.12% | |||
| Average Basic Shares Outstanding | 0.34% | 0.71% | |||
| Average Diluted Shares Outstanding | 0.34% | 0.71% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||